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Abstract The implementation of hepatitis C (HCV) direct-
acting antiviral drugs is prioritized in several populations in
which its application provides the most immediate and im-
pactful benefit. In this scenario, a precise knowledge of the
situation of human immunodeficiency virus (HIV)/HCV
chronic co-infection is required to adequately address this dis-
ease. This cross-sectional study was performed in 21 hospitals
in Andalusia (Spain). The study population consisted of HIV-
infected patients with an active HCV chronic infection who
were not receiving HCV treatment at the time of inclusion. A
total of 13,506 HIV-infected patients were included in the
study. Of them, 2561 (18.9 %) presented chronic HCV infec-
tion. The majority of the patients included were on highly
active antiretroviral therapy (HAART; 96.2 %), showed plas-
ma levels with an undetectable HIV viral load (92.5 %), and
had a good immunological status (median CD4+ cell count of
486 cells/mL). The HCV genotype distribution was as fol-
lows: 58.1 % were genotype 1, 1.1 % were genotype 2,
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16.1 % were genotype 3, and 22.1 % were genotype 4 (2.6 %
were missing data). In total, 24.8 % of the patients
showed liver fibrosis stage F0–F1, 27.9 % showed stage
F2, 16.7 % showed stage F3, and 21 % showed stage
F4 (9.6 % were missing data). With regards to previous
HCV treatment experiences, 68.05 % of the patients
were naïve and 31.95 % had failed to respond to a previous
treatment. The burden of HCV/HIV co-infected patients in
our population was reported as one in five HIV-infected
patients requiring HCV treatment. The implementation of
extra resources to face this important health challenge is
mandatory.
Introduction
The introduction of direct-acting antiviral (DAA) drugs
has supposed a significant improvement in the prognosis
of the hepatitis C virus (HCV) infection [1–6]. This
important advancement has substantially increased the
likelihood of achieving a sustained virological response
(SVR) using shorter and safer therapies [1–6]. In con-
sequence, the target population to be treated has ex-
panded significantly because the lack of clinical contra-
indications, mainly due to interferon (IFN), is no longer
a cornerstone of HCV treatment [7, 8].
It is estimated that ∼3 % of the world’s population (∼170
million people) is chronically infected with HCV, of which
approximately 350,000 die annually from complications relat-
ed to cirrhosis or hepatocellular carcinoma [9]. Among those
particularly affected is the group of patients with concurrent
human immunodeficiency virus (HIV) infection because both
infections share identical routes of transmission [10]. The re-
duction of morbidity and mortality and the increased survival
in patients with HIV infection, which is attributable to the
effectiveness of antiretroviral therapy, has currently allowed
HCV chronic liver disease to become a major cause of hospi-
talizations and mortality in these patients because survival is
significantly lower, regardless of other prognostic markers of
cirrhosis, compared to mono-infected patients [11–18].
Therefore, the HIV-infected population is a high-priority pop-
ulation that must receive immediate treatment against chronic
HCV infection [7].
In this scenario, precise knowledge of the situation of the
HIV/HCV chronic co-infection would facilitate the adequate
provision of personal and material resources required to ade-
quately address this disease in each center and in the commu-
nity as a whole. Thus, the aim of our study was to evaluate the
current situation of HCV chronic infection in HIV co-infected
patients. Given these drawbacks, we designed a study with the
objective of determining the dimension of the HCV chronic
infection among HIV-infected patients.
Methods
Study design and source of information
This prospective cross-sectional study was conducted in two
phases to address two specific objectives. During the
first phase, an inquiry was performed in 21 hospitals
that conformed to the HIV health care of the territory
(Fig. 1), with the objective of calculating the total HIV-
infected patient population. Once all the patients were
obtained at the end of the first phase, the second phase
selected hospitals with a significant number of patients
in active follow-up, excluding those that attended <100 pa-
tients. The objective of the second phase was to identify the
number of HIV-infected patients with active HCV chronic
infection. To assess this objective, a specific electronic form
(database) was facilitated to each hospital to record specific
clinical data of each chronic HCV-infected patient (defined as
the study population).
The study was designed, managed, and analyzed by all the
authors who reviewed the study data, guaranteed the reliabil-
ity of the data, conducted the study in accordance with the
protocol followed, and approved the decision to submit the
manuscript for publication.
Fig. 1 Patient flow diagram
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Setting
The study was performed in Andalusia, Spain (south Europe)
during June and December 2014. Andalusia is a south Europe
region with universal health coverage and a population of 8.3
million people. Andalusia features 21 hospitals encompassing
the entire territory that attend HIV-infected patients.
Participants
The study population consisted of HIV-infected patients with
an active HCV chronic infection, which was identified during
the second phase of the study. This population was de-
fined as: (i) patients with detectable plasmatic HCV-
RNA at the moment of inclusion and (ii) patients who
were not on HCV therapy at the moment of inclusion in
the study. Consequently, the data of patients with unde-
tectable HCV viral loads, including those with SVR or
with spontaneous viral clearance, were not collected in
the study.
Variable collection and definitions
The data were collected in electronic forms (database), includ-
ing the participant, demographic, clinical, and virological
characteristics. These data included age, gender, risk for
HCV infection, current use of antiretroviral therapy (yes or
no), current CD4+ cell count (cells/mL), current plasmatic
HIV viral load (copies/mL), current plasmatic HCV viral load
(IU/mL), HCV genotype/subtype, current liver fibrosis stage,
Child–Pugh–Turcotte (Child-PT) score (A, B, or C), history of
HCV therapy, and current use of HCV therapy.
An undetectable HIV viral load was defined as an HIV-1
RNA viral load of less than 50 copies per mL, using RT-PCR
(Cobas TaqMan; Roche Diagnostic Systems Inc., Pleasanton,
CA, USA). Liver fibrosis staging was performed by liver bi-
opsy (following the METAVIR fibrosis score) and/or liver
transient elastography (FibroScan; Echosens, Paris, France).
The liver fibrosis stages were grouped as follows: (i) F0–F1
METAVIR fibrosis score or LSM <7.2 kPa; (ii) F2 METAVIR
fibrosis score or LSM 7.2–8.9 kPa; (iii) F3 METAVIR fibrosis
score or LSM 9–14.5; and (iv) F4 METAVIR fibrosis score or
LSM ≥14.6 kPa. In the patients with liver cirrhosis, the Child-
PT score was calculated using the parameters hepatic enceph-
alopathy, ascites, total bilirubin, serum albumin, and pro-
thrombin time. According to the value obtained, the patients
were classified as follows: A (5–6 points), B (7–8 points), or C
(>9 points).
The study data were transcribed onto data collection forms
in which one code was assigned to each patient: the ID code.
Only the physician directly responsible for each patient and/or
authorized personnel had access to the medical history of the
patients according to Law 15/1999 of December 13,
Protection of Personal Data. This confidential information is
the exclusive property of the physician directly responsible for
patient care and may not be used except for conducting
this study. The information created during the conduct
of this clinical study is considered confidential and is/
will be used by researchers in relation to the objectives
of the study.
Statistical methods
The elaboration of the manuscript has been performed follow-
ing the Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE) recommendations. For the pur-
pose of the study, those patients on HCV treatment at the
moment of inquiry were excluded from the analysis. The de-
scriptive statistics of the patients were reported. The continu-
ous variables were summarized as the median and interquar-
tile range (IQR); meanwhile, the categorical variables were
expressed as frequencies/number of cases and percentages.
The categorical variables were compared using the Chi-
square test or Fisher’s exact test if the expected frequency of
any group was lower than 5 %.
The principal analysis consisted of the patient distribution
according to HCV genotype and liver fibrosis stage. A
secondary analysis was performed in which the HCV
genotype and liver fibrosis distribution were reported
by sorting the patients according to previous experience
with HCV treatment (including Peg-IFN/RBV and DAA-
based regimens).
Ethics issues
This study was conducted according to the principles of Good
Clinical Practice (Ministry of Health, Royal Decree 223/2004
of 6 February) and the Declaration of Helsinki; the protection
of personal data is guaranteed in accordance with Law 15/
1999 of 13 December on the Protection of Personal Data
and Royal Decree 1720/2007 of 21 December. The study
did not require informed consent because the patients were
not directly interviewed, and completely anonymous informa-
tion from existing records was collected, ensuring the protec-
tion of personal data in accordance with Law 15/1999 of 13
December on Personal Data Protection.
The study coordinator presented the study protocol (proto-
col code: HEP-COI-1-2014) to the Coordinating Ethics
Committee of Biomedical Research of Andalusia for evalua-
tion and obtained approval (05/14). Those responsible for the
providers of health services where the study occurred were
given a copy of the protocol and the documents evidencing
approval by the Ethics Committee in accordance with the
procedures and legal requirements.
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Results
Population tested
After the first phase, a total of 15,663 HIV-infected patients
were obtained in the prospective follow-up in our media (HIV
prevalence: 1.8 per 1000 inhabitants) (Fig. 1). For the second
phase, four hospitals were excluded because they had less than
100 patients in their follow-up of an HIV-infected population
(n=270). Consequently, 15,393HIV-infected patients (98.3 %
of the total population in follow-up) comprised the target pop-
ulation of the study.
Fourteen of the 17 hospitals included in the second phase
of the study agreed to participate (Fig. 1). Thus, the study
target population consisted of 13,506 patients (87.4 % of the
target population). Of this population, the presence of active
chronic HCVinfection was reported in 2711 patients (20.5%),
of which 150 patients (5.5 %) were on HCV treatment at
inclusion and were excluded from the analysis according to
the study protocol. Consequently, 2561 (18.9 %) HIV/HCV
chronically infected patients constituted the study population.
Patients
The baseline demographic and clinical characteristics are
shown in Table 1. The majority of the patients included were
on highly active antiretroviral therapy (HAART; 96.2 %),
showed undetectable plasma HIV viral loads (92.5 %), and
had a good immunological status (median CD4+ cell count:
486 cells/mL [308–697]). The most prevalent HCV genotype
was genotype 1 (58.1 %), with HCV subtype 1a being pre-
dominant in our population (38.3 %). In total, 21 % of the
patients (n=538) showed liver cirrhosis, with a Child-PTscore
of A in 65.8 % of the patients in this subset.
In regards to previous HCV treatment (Table 1), 68.05% of
the patients had not received previous therapy and, conse-
quently, 31.95 % had failed to respond to at least one previous
HCV treatment. Among the 818 patients with a previous treat-
ment failure, 60.7 % of patients did not complete the full
course of therapy because of the absence of a viral response,
16.6 % experienced a viral relapse after a full course of ther-
apy, and 22.7 % voluntarily dropped out of therapy or with-
drew because of adverse events.
Distribution according to HCV genotype and liver fibrosis
The patient distribution according to HCV genotype and liver
fibrosis stage is shown in Fig. 2. The liver fibrosis stage ap-
peared to be consistent across HCV genotypes. The highest
percentage of F4 patients was found among HCV genotype 3
patients (24.4 %). The highest percentage of F2 patients was
found in those bearing HCV genotype 4 (31.3 %) but was not
statistically significant. Among those patients with an
unavailable HCV genotype (n=65), 26.1 % were classified
as F4 liver fibrosis stage. The percentage of missing liver
fibrosis stages was greater than 10 % in the patients bearing
HCV genotypes 2, 3, and 4.
Distribution of HCV genotype and liver fibrosis according
to previous HCV treatment
The secondary analysis was performed to assess the HCV
genotype and liver fibrosis stage distribution according to pre-
vious HCV therapy (Fig. 3). This distribution among previ-
ously untreated and treatment-experienced patients is shown
in Fig. 3a, b, respectively. Globally, the percentage of F4 pa-
tients was the greatest among treatment-experienced patients
than previously untreated patients (30.4 % vs. 16.6 %,
p<0.001). In contrast, the percentage of F0–F1 patients was
higher among treatment-naïve patients (28.3 %) than in
treatment-experienced patients (16.9 %) (p<0.001). When
this association was analyzed in each treatment experience
group according to HCV genotype, no statistical association
was found.
Discussion
This is the first study showing the dimensions of HCV chronic
infection in HIV-infected patients by targeting one of the larg-
est HIV population samples. The burden of HCV/HIV co-
infected patients in our population reported that at least one
in five HIV-infected patients required HCV treatment.
Therefore, the implementation of extra resources to face this
important health challenge is mandatory.
In Europe, the most common HCV genotype is genotype 1
(specifically, genotype 1b), followed by genotype 3; there is a
relatively low frequency of genotypes 2 and 4 in the overall
HCV population [19]. Nevertheless, if the HCV genotype
distribution is focused among HIV co-infected patients, this
appears to change. HCV genotypes appear to have strong
epidemiological behavior; in other words, they have a close
relationship with HIV infection/transmission [19, 20]. The
main route of HCV transmission in HIV-infected patients
has been illegal injection drug use (IDU) [21]; in our study,
this route represented 87.7 % of the transmission. In this con-
text, the introduction of several HCV genotypes into networks
of IDU in Europe, such as genotypes 1a and 4 [19], has altered
the HCV genotype distribution in this population subset. This
point was confirmed in our study, in which HCV genotype 1
(specifically, genotype 1a) and HCV genotype 4 were the
most prevalent, as opposed to HCV genotype 3. This particu-
lar HCV genotype distribution converted these patients to
Bdifficult to treat patients^, mainly because of the significantly
low response rate to Peg-IFN/RBV therapy compared to HCV
genotypes 2 and 3 [22].
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Table 1 Baseline demographic and clinical characteristics of the study patients
Characteristic Global (n=2561) G-1a (n=572) G-1b (n=329) G-2 (n=28) G-3 (n=413) G-4 (n=565)
Age, yearsa 49 (45–52) 48 (44–53) 49 (45–52) 31 (26–57) 49 (45–52) 48 (45–52)
Age range, no. (%)
<40 133 (5.3) 35 (6.1) 18 (5.4) 2 (7.1) 18 (4.3) 32 (5.6)
41–50 1352 (52.8) 304 (53.1) 149 (45.2) 11 (39.2) 207 (50.1) 317 (56.1)
51–60 1017 (39.7) 220 (38.4) 148 (44.9) 14 (50) 170 (41.1) 206 (36.4)
>60 59 (2.2) 13 (2.4) 14 (4.5) 1 (3.7) 17 (4.5) 10 (1.9)
Gender, no. (%)
Male 2118 (82.7) 471 (82.3) 283 (86) 23 (82.1) 327 (79.1) 454 (80.3)
Female 443 (17.3) 101 (17.7) 46 (14) 5 (17.9) 86 (20.9) 111 (19.7)
Risk group for HCV infection, no. (%)
IDU 2248 (87.7) 499 (87.2) 279 (84.8) 24 (85.7) 349 (84.5) 495 (87.6)
Heterosexual 219 (8.5) 42 (7.5) 32 (9.7) 3 (10.7) 49 (11.8) 54 (9.5)
Homosexual 75 (2.9) 21 (3.6) 14 (4.2) 1 (3.6) 12 (2.9) 12 (2.1)
Blood derived 19 (0.9) 9 (1.7) 3 (1.3) 0 1 (0.8) 2 (0.8)
HAART, no. (%)
Receiving 2468 (96.2) 556 (97.2) 317 (96.3) 27 (96.4) 394 (95.3) 542 (95.9)
Non-receiving 93 (3.8) 16 (2.8) 12 (3.7) 1 (3.6) 19 (4.7) 23 (4.1)
HIV viral load, no. (%)b
Undetectable 2370 (92.5) 527 (92.1) 301 (91.4) 27 (96.4) 383 (92.7) 521 (92.2)
Detectable 191 (7.5) 38 (7.9) 21 (8.6) 1 (3.6) 26 (7.3) 42 (7.8)
CD4+ total count, cells/mLa 486 (308–697) 470 (328–702) 502 (304–694) 400 (278–699) 452 (321–693) 513 (394–721)
CD4+ cell grading, no. (%)
<200 cells/mL 339 (13.2) 83 (14.6) 31 (9.5) 1 (3.6) 62 (15.1) 64 (11.4)
≥200 cells/mL 2222 (86.8) 489 (85.4) 298 (90.5) 27 (96.4) 351 (84.9) 501 (88.6)
HCV genotype, no. (%)
Genotype 1 1490 (58.1) – – – – –
Genotype 2 28 (1.1) – – – – –
Genotype 3 413 (16.1) – – – – –
Genotype 4 565 (22.1) – – – – –
Non-genotyped 65 (2.6) – – – – –
HCV genotype 1 subtype, no. (%)
Genotype 1a 572 (38.3) – – – – –
Genotype 1b 329 (22.1) – – – – –
Other genotypec 41 (2.7) – – – – –
Non-subtyped 552 (36.9) – – – – –
Liver fibrosis stage, no. (%)d
F0–F1 636 (24.8) 147 (25.7) 79 (24) 8 (28.5) 89 (21.5) 145 (25.6)
F2 716 (27.9) 180 (31.4) 103 (31.3) 6 (21.4) 83 (20.1) 177 (31.3)
F3 428 (16.7) 81 (14.1) 52 (15.8) 5 (17.8) 81 (19.6) 95 (16.8)
F4 538 (21) 121 (21.1) 66 (20.1) 4 (14.2) 101 (24.4) 87 (15.5)
Not staged 243 (9.6) 43 (7.5) 29 (8.8) 5 (17.5) 59 (14.4) 61 (10.8)
Child-PT, no. (%)
A 345 (65.8) 74 (61.5) 43 (65.1) 4 (100) 65 (64.3) 49 (56.3)
B 53 (9.8) 10 (8.2) 4 (6) 0 14 (13.8) 10 (11.4)
C 17 (3.1) 8 (6.6) 1 (1.5) 0 1 (1.2) 3 (2.5)
Not available 123 (21.3) 29 (23.7) 18 (27.4) 0 21 (20.7) 26 (29.8)
HCV therapy previous experience, no. (%)
Naïve 1743 (68.05) 379 (66.2) 207 (62.9) 22 (78.5) 269 (65.1) 384 (67.9)
Non-responder to Peg-IFN/RBV 743 (29.01) 167 (29.1) 102 (31) 6 (21.5) 143 (34.6) 178 (31.5)
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IDU HCV-transmitted patients, specifically those co-
infected with HIV, show a faster liver fibrosis progression to
liver cirrhosis and end-stage liver disease [23, 24]. Mainly
because of this reason, historically, HIV-infected patients have
constituted the worst subset of HCV-infected patients.
However, this axiom was established during the era in which
HCV therapeutic management was insufficient in terms of
efficacy and safety. Taking this into account and considering
the availability of more effective antiviral drugs against HCV
and HIV infection, this situation may have changed. In our
study, the majority of patients were on HAART (96.2 %),
showed undetectable HIV viral loads (92.5 %), and had a
relatively good immunological situation (406 CD4+ cells/
mL median value). This population (likely comparable to the
population followed in other countries with universal health
care coverage) matched the population included in clinical
trials in which the safety and efficacy of HCV DAA drugs
were tested in HIV-infected patients. In these trials, the SVR
rates obtained were similar to those obtained in non-HIV co-
infected patients, across liver fibrosis stages, genotype, or
Table 1 (continued)
Characteristic Global (n=2561) G-1a (n=572) G-1b (n=329) G-2 (n=28) G-3 (n=413) G-4 (n=565)
Non-responder to DAA-based regimen 75 (2.94) 26 (4.7) 20 (6.1) 0 1 (0.3) 3 (0.6)
Previous response to Peg-IFN/RBV, no. (%)
Non-responders 451 (60.7) 93 (55.6) 53 (51.9) 6 (100) 35 (24.4) 130 (73)
Viral relapse 123 (16.5) 21 (12.5) 19 (18.6) 0 63 (44) 25 (14)
Therapy withdrawne 169 (22.8) 53 (31.9) 30 (29.5) 0 45 (31.6) 23 (13)
Previous response to DAA-based regimen, no. (%)
Non-responders 46 (61.3) 5 (19.2) 7 (37.1) 0 0 2 (66.6)
Viral relapse 13 (17.3) 17 (65.3) 11 (54.2) 0 1 (100) 0
Therapy withdrawne 16 (21.4) 4 (15,5) 2 (18.7) 0 0 1 (33.4)
IFN-based therapy contraindication, no. (%)f 198 (7.7) 41 (7.1) 26 (7.9) 1 (3.5) 43 (10.4) 33 (5.8)
Alcohol abuse, no. (%)g 55 (2.1) 16 (2.7) 6 (1.8) 1 (3.5) 7 (1.6) 8 (1.4)
Number of cases (no.); percentage (%); genotype 1a (G-1a); genotype 1b (G-1b); genotype 2 (G-2); genotype 3 (G-3); genotype 4 (G-4); hepatitis C virus
(HCV); injecting drug user (IDU); highly active antiretroviral therapy (HAART); human immunodeficiency virus (HIV); milliliter (mL); Child–Pugh–
Turcotte score (Child-PT); pegylated interferon plus ribavirin (Peg-IFN/RBV); direct-acting antiviral (DAA) agent
a Expressed as the median (interquartile range)
b Undetectable plasmatic HIV viral loads were defined as HIV-RNA <50 IU/mL
cGenotypes 1c or 1a/b
d Liver fibrosis was measured by liver biopsy or liver stiffness
e Patients who voluntarily dropped out of therapy or withdrew because of adverse events
f Including patients with severe adverse events to previous interferon-based therapy, advanced or decompensated liver cirrhosis, oncological patients,
those with severe renal impairment, uncontrolled psychiatric disorders, or autoimmune diseases
g Defined as a daily alcohol ingestion >100 mg
Fig. 2 Liver fibrosis stage
distribution according to hepatitis
C virus (HCV) genotype in the
total population included. The
distribution is expressed as the
cumulative percentage in each
HCV genotype column. HCV
genotype 1 (G-1), HCV genotype
2 (G-2), HCV genotype 3 (G-3),
HCV genotype 4 (G-4), HCV
genotype undetermined (NG),
liver fibrosis stage undetermined
(N/A)
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previous treatment experience [25–27]. Therefore, HIV infec-
tion should not remain an associated risk factor to achieve a
successful HCV treatment outcome in the new DAA era and
should benefit from the same treatment regimen and strategies
as HCV mono-infected patients. On the other hand, more than
40 % of our population was aged more than 50 years. This
establishes a high sensitivity population due to polymedication
(including HAART drugs) and age-associated pathologies, sup-
posing a higher drug–drug interaction complicating the man-
agement of this population using HCV DAA drugs.
The HCV clinical guidelines identify those HCV-infected
patients at the highest risk for severe hepatic complications [7,
8]. The main reason is that this population includes patients in
whomHCV therapy provides the most immediate and impact-
ful benefit [28, 29]. Our study shows that an important burden
of the highest priority patients require an immediate treatment
implementation to improve life expectancy and avoid both
liver and non-liver-related complications. According to liver
fibrosis stage, in our study, the proportion of patients with a
liver fibrosis stage of F3 or F4 increased to 37.7 %, with the
highest representation of patients who had failed to respond to
a previous treatment. However, the different distribution of the
F4 population according to previous HCV treatment experi-
ence was potentially a result of the prioritization of HCV
treatment when non-highly successful drugs were available.
HCV genotype 3 has been considered one of the best scenar-
ios under the Peg-IFN/RBV therapy. Nevertheless, those pa-
tients who have currently failed to respond to a previous treat-
ment and with liver cirrhosis staging (35.1 % in our popula-
tion) do not have a good prognosis [30]. This is because, by
applying the treatment regimens currently recommended in
this population, the expected SVR rate would be approximate-
ly 60 %, which is clearly insufficient compared to the SVR
rate achieved in the same population in other genotypes.
Therefore, this represents a priority treatment population with
an expected lower healing rate. Consequently, specific treat-
ment strategies must be investigated in this population.
Our study has several limitations. Firstly, it should be noted
that 9.6 % of patients had missing liver fibrosis stage data.
Secondly, although the percentage of ungenotyped patients
was relatively low (2.6 %), the percentage of HCV genotype
1 patients who were unsubtyped was 36.9 %. Nevertheless,
the missing data were distributed across all hospitals; thus, the
reported liver fibrosis stage and HCV genotype distribution
Fig. 3 Liver fibrosis stage
distribution according to HCV
genotype in treatment-naïve (a)
and treatment-experienced pa-
tients (b). The patients with pre-
vious treatment failure to
pegylated-interferon plus ribavi-
rin (Peg-IFN/RBV) or direct-
acting antiviral (DAA) drugs
therapy were grouped for the
analysis. The distribution is
expressed as the cumulative per-
centage in each HCV genotype
column. HCV genotype 1 (G-1),
HCV genotype 2 (G-2), HCV
genotype 3 (G-3), HCV genotype
4 (G-4), HCV genotype undeter-
mined (NG), liver fibrosis stage
undetermined (N/A)
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could not change significantly. This point supports the fact
that the implementation of extra resources is mandatory to
obtain the best management and care for HCV infection.
In conclusion, our results reveal the current magnitude of
this disease, showing that, during the next few years, HCV
treatment should be a mandatory clinical provision in HIV-
infected patients. In this situation, acquiring additional re-
sources to proportionate the best clinical care options in this
highly sensitive population is a priority. In a public health care
system, such as those in Spanish and most European coun-
tries, this supposes an important amount of resources to inten-
sify care management in this area.
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